The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Itraconazole Prevents Invasive Fungal Infections in Neutropenic Patients Treated for Hematologic Malignancies: Evidence From a Meta-Analysis of 3,597 Patients
Abstract
Purpose: Efficacy of antifungal prophylaxis has not yet been convincingly proven in numerous trials of various antifungals. New evidence and the anti-Aspergillus efficacy of itraconazole prompted a new look at the data for the prevention of invasive fungal infections. Patients and Methods: Randomized, controlled studies with itraconazole for antifungal prophylaxis in neutropenic patients with hematologic malignancies were identified from electronic databases and hand searching. Results: Thirteen randomized trials included 3,597 patients who were assessable for invasive fungal infections. Itraconazole reduced the incidence of invasive fungal infection (mean relative risk reduction, 40% ± 13%; P = .002), the incidence of invasive yeast infections (mean, 53% ± 19%; P = .004) and the mortality from invasive fungal infections (mean, 35% ± 17%; P = .04) significantly. The incidence of invasive Aspergillus infections was only reduced in trials using the itraconazole cyclodextrine solution (mean, 48% ± 21%; P = .02) and not itraconazole capsules (mean, 75% ± 73% increase; P = .3). The overall mortality was not changed. Adverse effects were rare, hypokalemia was noted in three studies, and a higher rate of drug discontinuation was found in trials that compared itraconazole cyclodextrine solution to a control without cyclodextrine. The effect of prophylaxis was clearly associated with a higher bioavailable dose of itraconazole. Conclusion: Antifungal prophylaxis with itraconazole effectively prevents proven invasive fungal infections and—shown for the first time for antifungal prophylaxis—reduces mortality from these infections and the rate of invasive Aspergillus infections in neutropenic patients with hematologic malignancies. Adequate doses of the oral cyclodextrine solution (at least 400 mg/d) or IV formulations (200 mg/d) of itraconazole are necessary for these effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
Aspergillosis Case-Fatality Rate: Systematic Review of the Literature
Lin, S.-J., Schranz, J., & Teutsch, S. M. (2001) · Clinical Infectious Diseases · doi:10.1086/318483 · Cited by 1,409
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Wald, A., Leisenring, W., van Burik, J., & Bowden, R. A. (1997) · The Journal of Infectious Diseases · doi:10.1086/516480 · Cited by 742
Grant, S. M., & Clissold, S. P. (1990) · Drugs · doi:10.2165/00003495-199039060-00006 · Cited by 661
Viscoli, C., Girmenia, C., Marinus, A., Collette, L., Martino, P., Vandercam, B., Doyen, C., Lebeau, B., Spence, D., Krcmery, V., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/514731 · Cited by 601
Marr, K. A., Seidel, K., Slavin, M. A., Bowden, R. A., Schoch, H. G., Flowers, M. E. D., Corey, L., & Boeckh, M. (2000) · Blood · doi:10.1182/blood.v96.6.2055 · Cited by 511
Marr, K. A., Seidel, K., White, T. C., & Bowden, R. A. (2000) · The Journal of Infectious Diseases · doi:10.1086/315193 · Cited by 493
The Clinical Pharmacokinetics of Itraconazole: An Overview
Heykants, J., Van Peer, A., Van de Velde, V., Van Rooy, P., Meuldermans, W., Lavrijsen, K., Woestenborghs, R., Van Cutsem, J., & Cauwenbergh, G. (1989) · Mycoses · doi:10.1111/j.1439-0507.1989.tb02296.x · Cited by 404
Winston, D. J., Maziarz, R. T., Chandrasekar, P. H., Lazarus, H. M., Goldman, M., Blumer, J. L., Leitz, G. J., & Territo, M. C. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-9-200305060-00006 · Cited by 389
The direct cost and incidence of systemic fungal infections
Wilson, L. S., Reyes, C. M., Stolpman, M., Speckman, J., Allen, K., & Beney, J. (2002) · Value in Health · doi:10.1046/j.1524-4733.2002.51108.x · Cited by 374
Grant, S. M., & Clissold, S. P. (1989) · Drugs · doi:10.2165/00003495-198937030-00003 · Cited by 361
Bow, E. J., Laverdière, M., Lussier, N., Rotstein, C., Cheang, M. S., & Ioannou, S. (2002) · Cancer · doi:10.1002/cncr.10610 · Cited by 258
Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients
Jantunen, E., Ruutu, P., Niskanen, L., Volin, L., Parkkali, T., Koukila-Kähkölä, P., & Ruutu, T. (1997) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1700737 · Cited by 251
Menichetti, F., Del Favero, A., Martino, P., Bucaneve, G., Micozzi, A., Girmenia, C., Barbabietola, G., Pagano, L., Leoni, P., Specchia, G., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/515129 · Cited by 244
Morgenstern, G. R., Prentice, A. G., Grant Prentice, H., Ropner, J. E., Schey, S. A., Warnock, D. W., & on behalf of the U.K. Multicentre Antifungal Prophylaxis Study Group (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01465.x · Cited by 201
Self-citationOrganism-Dependent Fungicidal Activities of Azoles
Manavathu, E. K., Cutright, J. L., & Chandrasekar, P. H. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.11.3018 · Cited by 190
Antifungal Prophylaxis with Itraconazole in Prolonged Neutropenia: Correlation with Plasma Levels
Boogaerts, M. A., Verhoef, G. E., Zachee, P., Demuynck, H., Verbist, L., & De Beule, K. (1989) · Mycoses · doi:10.1111/j.1439-0507.1989.tb02299.x · Cited by 189
Towards a targeted, risk‐based, antifungal strategy in neutropenic patients
Prentice, H. G., Kibbler, C. C., & Prentice, A. G. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02014.x · Cited by 181
Self-citationProphylactic action of oral fluconazole against fungal infection in neutropenic patients
Kanda, Y., Yamamoto, R., Chizuka, A., Hamaki, T., Suguro, M., Arai, C., Matsuyama, T., Takezako, N., Miwa, A., Kern, W., et al. (2000) · Cancer · doi:10.1002/1097-0142(20001001)89:7<1611::aid-cncr27>3.0.co;2-b · Cited by 154
Harousseau, J., Dekker, A. W., Stamatoullas, A., Fassas, Α., Linkesch, W., Gouveia, J., Bock, R. D., Rovira, M., Seifert, W., Joosen, H., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.7.1887-1893.2000 · Cited by 151
Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole
Glasmacher, A. G., Hahn, C., Leutner, C., Molitor, E., Wardelmann, E., Losem, C. J., Sauerbruch, T., Marklein, G., & Schmidt‐Wolf, I. G. H. (1999) · Mycoses · doi:10.1046/j.1439-0507.1999.00505.x · Cited by 147
Self-citationOdds, F. C., Gerven, F. V., Espinel‐Ingroff, A., Bartlett, M. S., Ghannoum, M. A., Lancaster, M. V., Pfaller, M. A., Rex, J. H., Rinaldi, M. G., & Walsh, T. J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.282 · Cited by 146
Kanda, Y., Yamamoto, R., Chizuka, A., Hamaki, T., Suguro, M., Arai, C., Matsuyama, T., Takezako, N., Miwa, A., Kern, W., et al. (2000) · PubMed · Cited by 137
Groll, A. H., Wood, L., Roden, M., Mickiene, D., Chiou, C. C., Townley, E., Dad, L., Piscitelli, S. C., & Walsh, T. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2554-2563.2002 · Cited by 123
Nucci, M., Biasoli, I., Akiti, T., Silveira, F., Solza, C., Barreiros, G., Spector, N., Derossi, A., & Pulcheri, W. (2000) · Clinical Infectious Diseases · doi:10.1086/313654 · Cited by 113
Gotzsche, P. C., & Johansen, H. (1997) · BMJ · doi:10.1136/bmj.314.7089.1238 · Cited by 105
Glasmacher, A. G., Hahn, C., Molitor, E., Marklein, G., Sauerbruch, T., & Schmidt‐Wolf, I. G. H. (1999) · Mycoses · doi:10.1046/j.1439-0507.1999.00518.x · Cited by 99
Self-citationItraconazole: pharmacology, clinical experience and future development
De Beule, K. (1996) · International Journal of Antimicrobial Agents · doi:10.1016/0924-8579(95)00043-7 · Cited by 96
Vreugdenhil, G., van Dijke, B. J., Donnelly, J. P., Nováková, I. R. O., Raemaekers, J. M. M., Hoogkamp-Korstanje, M. A. A., Koster, M., & Pauw, B. E. D. (1993) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199309067926 · Cited by 94
Prentice, A., Warnock, D. W., Johnson, S. A., Phillips, M. J., & Oliver, D. A. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/34.2.247 · Cited by 92
Self-citationPrentice, A. G., Warnock, D. W., Johnson, S. A., Taylor, P. C., & Oliver, D. (1995) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/36.4.657 · Cited by 74
Self-citationBerenguer, J., Ali, N. A. S., Allende, M. C., Lee, J. K., Garrett, K. F., Battaglia, S., Piscitelli, S. C., Rinaldi, M. G., Pizzo, P. A., & Walsh, T. J. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.6.1303 · Cited by 74
Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology.
Huijgens, P. C., Simoons‐Smit, A. M., Loenen, A. C. V., Prooy, E., van Tinteren, H., Ossenkoppele, G. J., & Jonkhoff, A. R. (1999) · Journal of Clinical Pathology · doi:10.1136/jcp.52.5.376 · Cited by 72
Gøtzsche, P. C., & Johansen, H. K. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000026.pub2 · Cited by 63
Boogaerts, M. A., Maertens, J., van Hoof, A., de Bock, R., Fillet, G., Peetermans, M., Selleslag, D., Vandercam, B., Vandewoude, K., Zachée, P., et al. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.1.97 · Cited by 55
Gøtzsche, P. C., & Johansen, H. K. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000026 · Cited by 51
Efficacy of different prophylactic antifungal regimens in bone marrow transplantation.
Annaloro, C., Oriana, A., Tagliaferri, E., Bertolli, V. G., Volpe, A. D., Soligo, D. A., Ibatici, A., Pozzoli, E. F., & Deliliers, G. L. (1995) · PubMed · Cited by 48
Lass‐Flörl, C., Gunsilius, E., GASTL, G. A., Englisch, M., Koch, G., Ulmer, H., Dierich, M. P., & Petzer, A. (2003) · Annals of Hematology · doi:10.1007/s00277-003-0666-5 · Cited by 43
Bradford, C. R., Prentice, A., Warnock, D. W., & Copplestone, J. A. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.4.555 · Cited by 41
Self-citationFlynn, T. N., Kelsey, S. M., Hazel, D. L., & Guest, J. F. (1999) · PharmacoEconomics · doi:10.2165/00019053-199916050-00010 · Cited by 31
Itraconazole is not effective for the prophylaxis of fungal infections in patients with neutropenia
Kaptan, K., Ural, A. U., Çetin, T., Avcu, F., Beyan, C., & Yalçın, A. (2003) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-002-0207-5 · Cited by 27
Cited by
Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir073 · Cited by 3,463
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Walsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,706
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
Cornely, O. A., Maertens, J., Winston, D. J., Perfect, J., Ullmann, A. J., Walsh, T. J., Helfgott, D., Holowiecki, J., Stockelberg, D., Goh, Y.-T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061094 · Cited by 1,813
Metadata
- Authors
- Glasmacher, A., Prentice, A., Gorschlüter, M., Engelhart, S., Hahn, C., Djulbegovic, B., & Schmidt-Wolf, I. G. H.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-12-15
- Volume
- 21
- Issue
- 24
- Pages
- 4615-4626
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1971548861
- Cited by
- 264
- References
- 43
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.